Thrivent Financial for Lutherans Sells 591 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Thrivent Financial for Lutherans cut its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 1.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 42,682 shares of the specialty pharmaceutical company’s stock after selling 591 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.08% of Supernus Pharmaceuticals worth $1,543,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Intech Investment Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 16.2% in the 3rd quarter. Intech Investment Management LLC now owns 13,161 shares of the specialty pharmaceutical company’s stock worth $410,000 after buying an additional 1,838 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Supernus Pharmaceuticals by 14.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock worth $22,212,000 after purchasing an additional 91,354 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Supernus Pharmaceuticals in the third quarter valued at $352,000. FMR LLC raised its stake in Supernus Pharmaceuticals by 101.1% in the 3rd quarter. FMR LLC now owns 16,903 shares of the specialty pharmaceutical company’s stock valued at $527,000 after acquiring an additional 8,499 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in shares of Supernus Pharmaceuticals by 15.2% in the third quarter. BNP Paribas Financial Markets now owns 84,077 shares of the specialty pharmaceutical company’s stock worth $2,622,000 after purchasing an additional 11,125 shares in the last quarter.

Insider Transactions at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 700 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,103.38. This represents a 6.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jonathan Rubin sold 927 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, March 24th.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $32.29 on Monday. The company’s 50 day simple moving average is $35.15 and its two-hundred day simple moving average is $35.04. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28. The stock has a market capitalization of $1.80 billion, a PE ratio of 30.18 and a beta of 0.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.